Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conbercept + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Chengdu Kanghong Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
KH903 (conbercept) in combination with paclitaxel is an investigational therapeutic regimen being developed by Chengdu Kanghong Biotech for the treatment of advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma. Conbercept is a recombinant fusion protein biologic that functions as a VEGF trap; it is composed of the second immunoglobulin-like domain of VEGF receptor 1 (VEGFR1) and the third and fourth domains of VEGF receptor 2 (VEGFR2) fused to the Fc fragment of human IgG1. This decoy receptor binds with high affinity to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting tumor angiogenesis and depriving the tumor of necessary blood supply and nutrients. Paclitaxel is a cytotoxic chemotherapy agent that stabilizes microtubules, leading to cell cycle arrest and apoptosis. The combination is currently being evaluated in Phase 2 clinical trials as a second-line treatment for patients who have progressed after initial platinum and fluoropyrimidine-based therapy.
- Brand names
- Abraxane
- Other names
- KH903 + paclitaxelconbercept + paclitaxel
02
Targets
PGF (Placental Growth Factor)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on conbercept + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conbercept + paclitaxel.